tiprankstipranks
Advertisement
Advertisement

HK:6628 Stock Latest News

Transcenta Returns Two Lilly-Licensed Compounds in US$4 Million Deal, Retains Blosozumab Rights
Company AnnouncementsTranscenta Returns Two Lilly-Licensed Compounds in US$4 Million Deal, Retains Blosozumab Rights
6d ago
6628
Transcenta Grants New Share Awards and Options to Strengthen Staff Incentives
PremiumCompany Announcements
Transcenta Grants New Share Awards and Options to Strengthen Staff Incentives
13d ago
6628
Transcenta AGM Approvals Leave Board Short of Independence Targets
PremiumCompany Announcements
Transcenta AGM Approvals Leave Board Short of Independence Targets
13d ago
6628
Transcenta Clarifies Board Line-Up and Committee Roles
PremiumCompany Announcements
Transcenta Clarifies Board Line-Up and Committee Roles
13d ago
6628
Transcenta Sets 2026 AGM to Approve Board Changes and Capital Mandates
PremiumCompany Announcements
Transcenta Sets 2026 AGM to Approve Board Changes and Capital Mandates
1M ago
6628
Transcenta Strengthens Board With Proposed Appointment of Two Biotech Veterans
PremiumCompany AnnouncementsTranscenta Strengthens Board With Proposed Appointment of Two Biotech Veterans
1M ago
6628
Transcenta Secures HiCB Milestone Payment as CDMO Pipeline Expands
Premium
Company Announcements
Transcenta Secures HiCB Milestone Payment as CDMO Pipeline Expands
2M ago
6628
Transcenta Gains Boost as Inhibrx’s Ozekibart Data and FDA Filing Strengthen Greater China Cancer Franchise
Premium
Company Announcements
Transcenta Gains Boost as Inhibrx’s Ozekibart Data and FDA Filing Strengthen Greater China Cancer Franchise
2M ago
6628
Transcenta Postpones AGM and Adjusts Share Register Closure Dates
PremiumCompany Announcements
Transcenta Postpones AGM and Adjusts Share Register Closure Dates
2M ago
6628
Transcenta Reports Strong Preclinical Results for LIV1-Targeting ADCs in Breast and Prostate Cancers
PremiumCompany Announcements
Transcenta Reports Strong Preclinical Results for LIV1-Targeting ADCs in Breast and Prostate Cancers
3M ago
6628
Transcenta Revamps Chinese Stock Short Name and Corporate Logo to Sharpen Biopharma Focus
PremiumCompany Announcements
Transcenta Revamps Chinese Stock Short Name and Corporate Logo to Sharpen Biopharma Focus
3M ago
6628
Transcenta Narrows Annual Loss on Cost Cuts Despite Revenue Decline
PremiumCompany Announcements
Transcenta Narrows Annual Loss on Cost Cuts Despite Revenue Decline
3M ago
6628
Transcenta Sets Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
PremiumCompany AnnouncementsTranscenta Sets Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
4M ago
6628
Transcenta Tightens Costs and Bolsters Liquidity Ahead of Oppenheimer Conference
Premium
Company Announcements
Transcenta Tightens Costs and Bolsters Liquidity Ahead of Oppenheimer Conference
5M ago
6628
Transcenta Advances Dealmaking, Licensing and Financing to Resolve Audit Disclaimer and Bolster Liquidity
Premium
Company Announcements
Transcenta Advances Dealmaking, Licensing and Financing to Resolve Audit Disclaimer and Bolster Liquidity
6M ago
6628
Transcenta Grants 2 Million Incentive Shares to Key Employee Under Performance-Linked Scheme
PremiumCompany Announcements
Transcenta Grants 2 Million Incentive Shares to Key Employee Under Performance-Linked Scheme
7M ago
6628
Transcenta Licenses HiCB Biomanufacturing Platform to EirGenix in Strategic Collaboration
PremiumCompany Announcements
Transcenta Licenses HiCB Biomanufacturing Platform to EirGenix in Strategic Collaboration
7M ago
6628
Transcenta’s Osemitamab Shows Promising Results in Cancer Trial
PremiumCompany Announcements
Transcenta’s Osemitamab Shows Promising Results in Cancer Trial
7M ago
6628
Transcenta Announces Share and Option Grants to Boost Strategic Goals
PremiumCompany Announcements
Transcenta Announces Share and Option Grants to Boost Strategic Goals
8M ago
6628
Transcenta Holding Limited Announces Auditor Change to Ernst & Young
PremiumCompany AnnouncementsTranscenta Holding Limited Announces Auditor Change to Ernst & Young
8M ago
6628
Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
Premium
Company Announcements
Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
9M ago
6628
Transcenta Advances Financial and Strategic Initiatives to Strengthen Position
Premium
Company Announcements
Transcenta Advances Financial and Strategic Initiatives to Strengthen Position
9M ago
6628

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >